BR0010593A - Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv - Google Patents
Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hivInfo
- Publication number
- BR0010593A BR0010593A BR0010593-7A BR0010593A BR0010593A BR 0010593 A BR0010593 A BR 0010593A BR 0010593 A BR0010593 A BR 0010593A BR 0010593 A BR0010593 A BR 0010593A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- ccr5
- pegylated
- combination therapy
- interferon alpha
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940105188 Interferon alpha antagonist Drugs 0.000 title 1
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 108010032976 Enfuvirtide Proteins 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 229960002062 enfuvirtide Drugs 0.000 abstract 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30489799A | 1999-05-04 | 1999-05-04 | |
| PCT/US2000/011634 WO2000066141A2 (en) | 1999-05-04 | 2000-05-01 | Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0010593A true BR0010593A (pt) | 2002-02-13 |
Family
ID=23178462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0010593-7A BR0010593A (pt) | 1999-05-04 | 2000-05-01 | Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1175224B1 (https=) |
| JP (1) | JP2002543144A (https=) |
| CN (1) | CN1349408A (https=) |
| AR (1) | AR023824A1 (https=) |
| AT (1) | ATE289516T1 (https=) |
| AU (1) | AU776541B2 (https=) |
| BR (1) | BR0010593A (https=) |
| CA (1) | CA2365900A1 (https=) |
| DE (1) | DE60018273T2 (https=) |
| ES (1) | ES2238277T3 (https=) |
| HK (1) | HK1039278B (https=) |
| HU (1) | HUP0202734A3 (https=) |
| MX (1) | MXPA01011116A (https=) |
| MY (1) | MY127670A (https=) |
| NO (1) | NO328679B1 (https=) |
| NZ (1) | NZ514519A (https=) |
| PE (1) | PE20010283A1 (https=) |
| PT (1) | PT1175224E (https=) |
| TW (1) | TWI289454B (https=) |
| WO (1) | WO2000066141A2 (https=) |
| ZA (1) | ZA200108870B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
| RU2366655C2 (ru) | 2003-03-14 | 2009-09-10 | Оно Фармасьютикал Ко., Лтд. | Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
| WO2004092169A1 (ja) | 2003-04-18 | 2004-10-28 | Ono Pharmaceutical Co., Ltd. | スピロピペリジン化合物およびその医薬用途 |
| US20070043079A1 (en) * | 2003-04-18 | 2007-02-22 | Hiromu Habashita | Heterocyclic compound containing nitrogen atom and use thereof |
| ES2294589T3 (es) | 2004-04-29 | 2008-04-01 | F. Hoffmann-La Roche Ag | Variacion de la secuencia nucleosida de ns5a como marcador. |
| US8143404B2 (en) | 2004-09-13 | 2012-03-27 | Ono Pharmaceutical Co., Ltd | Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient |
| EP1858887A1 (en) * | 2005-02-23 | 2007-11-28 | Schering Corporation | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| EP1889622A4 (en) | 2005-05-31 | 2009-12-23 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
| EP2657235A1 (en) | 2005-10-28 | 2013-10-30 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| JP5245827B2 (ja) | 2006-07-31 | 2013-07-24 | 小野薬品工業株式会社 | スピロ結合した環状基を含有する化合物およびその用途 |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| SG10201908048QA (en) | 2014-01-08 | 2019-10-30 | Immunovative Therapies Ltd | Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| DE69632062T2 (de) * | 1995-11-02 | 2004-11-18 | Schering Corp. | Kontinuierliche, niedrigdosierte zytokine-infusionstherapie |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| AU5522498A (en) * | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
-
2000
- 2000-05-01 BR BR0010593-7A patent/BR0010593A/pt not_active Application Discontinuation
- 2000-05-01 AT AT00928604T patent/ATE289516T1/de not_active IP Right Cessation
- 2000-05-01 DE DE60018273T patent/DE60018273T2/de not_active Expired - Lifetime
- 2000-05-01 WO PCT/US2000/011634 patent/WO2000066141A2/en not_active Ceased
- 2000-05-01 MX MXPA01011116A patent/MXPA01011116A/es active IP Right Grant
- 2000-05-01 EP EP00928604A patent/EP1175224B1/en not_active Expired - Lifetime
- 2000-05-01 CN CN00807116A patent/CN1349408A/zh active Pending
- 2000-05-01 HU HU0202734A patent/HUP0202734A3/hu unknown
- 2000-05-01 CA CA002365900A patent/CA2365900A1/en not_active Abandoned
- 2000-05-01 JP JP2000615025A patent/JP2002543144A/ja not_active Ceased
- 2000-05-01 ES ES00928604T patent/ES2238277T3/es not_active Expired - Lifetime
- 2000-05-01 AU AU46815/00A patent/AU776541B2/en not_active Ceased
- 2000-05-01 NZ NZ514519A patent/NZ514519A/en not_active IP Right Cessation
- 2000-05-01 HK HK02100826.8A patent/HK1039278B/en not_active IP Right Cessation
- 2000-05-01 PT PT00928604T patent/PT1175224E/pt unknown
- 2000-05-02 TW TW089108323A patent/TWI289454B/zh not_active IP Right Cessation
- 2000-05-02 PE PE2000000408A patent/PE20010283A1/es not_active Application Discontinuation
- 2000-05-02 AR ARP000102097A patent/AR023824A1/es unknown
- 2000-05-02 MY MYPI20001893A patent/MY127670A/en unknown
-
2001
- 2001-10-26 ZA ZA200108870A patent/ZA200108870B/xx unknown
- 2001-11-02 NO NO20015367A patent/NO328679B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1039278B (en) | 2005-06-30 |
| PE20010283A1 (es) | 2001-03-16 |
| AR023824A1 (es) | 2002-09-04 |
| JP2002543144A (ja) | 2002-12-17 |
| MXPA01011116A (es) | 2002-06-04 |
| DE60018273D1 (de) | 2005-03-31 |
| NO20015367L (no) | 2002-01-03 |
| DE60018273T2 (de) | 2005-08-18 |
| NZ514519A (en) | 2003-07-25 |
| ES2238277T3 (es) | 2005-09-01 |
| WO2000066141A3 (en) | 2001-02-08 |
| CN1349408A (zh) | 2002-05-15 |
| HUP0202734A2 (hu) | 2002-12-28 |
| MY127670A (en) | 2006-12-29 |
| CA2365900A1 (en) | 2000-11-09 |
| PT1175224E (pt) | 2005-07-29 |
| NO328679B1 (no) | 2010-04-26 |
| AU4681500A (en) | 2000-11-17 |
| TWI289454B (en) | 2007-11-11 |
| WO2000066141A2 (en) | 2000-11-09 |
| HUP0202734A3 (en) | 2003-11-28 |
| NO20015367D0 (no) | 2001-11-02 |
| EP1175224A2 (en) | 2002-01-30 |
| HK1039278A1 (en) | 2002-04-19 |
| AU776541B2 (en) | 2004-09-16 |
| EP1175224B1 (en) | 2005-02-23 |
| ATE289516T1 (de) | 2005-03-15 |
| ZA200108870B (en) | 2003-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0010593A (pt) | Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv | |
| BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
| BR9910505A (pt) | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c | |
| ES2251196T3 (es) | Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica. | |
| PE119199A1 (es) | Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica | |
| BR9809425A (pt) | Conjugados alfa interferon-polietilenoglicol para terapia de infecção | |
| BRPI0108435B8 (pt) | formulação e uso de entecavir de baixa dose | |
| BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| BR9810745A (pt) | Derivados de benzimidazol | |
| BR9911071A (pt) | Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépticos e/ou agentes promotores da cura de feridas no trato respiratório superior e/ou no ouvido | |
| BR9807112A (pt) | Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato | |
| BR0108997A (pt) | Terapia imune adjuvante para hiv | |
| PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
| PT91524A (pt) | Processo de preparacao de um medicamento a base de fraccoes e/ou fragmentos de heparina | |
| HUP0202525A2 (hu) | Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit | |
| BR9807473A (pt) | Tratamentos de doença relacionados à citocina | |
| BR9915644A (pt) | Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus | |
| ATE295729T1 (de) | Verwendung von einem mittel zur unterdrückung der infektion und der proliferation von hiv | |
| BR0212917A (pt) | Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento | |
| WO2000051631A3 (en) | Pegylated alpha interferon for hiv therapy | |
| BR9713514A (pt) | Novo uso de creatina | |
| BRPI0409711A (pt) | tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina | |
| ECSP003462A (es) | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k) | |
| KR950702838A (ko) | 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM ART. 24, ART. 8O COMBINADO COM ART. 11, ART. 10, ART. 25 E ART. 6 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |